Guanoxan
Chemical compound
- C02CC03 (WHO)
- 2-(2,3-Dihydro-1,4-benzodioxin-2-ylmethyl)guanidine
- 2165-19-7 Y
- 16564
- 15704 N
- 9V0MRL0R5Y
- DTXSID3046166
- Interactive image
- c1ccc2c(c1)OCC(O2)CNC(=N)N
InChI
- InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13) N
- Key:HIUVKVDQFXDZHU-UHFFFAOYSA-N N
Guanoxan is a sympatholytic drug that was marketed as Envacar by Pfizer in the UK to treat high blood pressure. It was not widely used and was eventually withdrawn from the market due to liver toxicity.[1][2]
References
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e